Capital Performance Advisors’s Novavax NVAX Stock Holding History

Capital Performance Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-41	Closed	-$518	–	1824
2024 Q3	$518	Buy	+41	New	+$529	﹤0.01%	2234

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Capital Performance Advisors's NVAX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Novavax (NVAX) in Q4 2024, closing a stake of 41 shares — an estimated $518 sold.

Capital Performance Advisors first reported a position in NVAX in Q3 2024 and held it in 1 quarter. The position peaked at $518 in Q3 2024. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

Capital Performance Advisors reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
Capital Performance Advisors sold 41 Novavax shares in Q4 2024, an estimated $518.
Capital Performance Advisors first reported a position in Novavax in Q3 2024 and held it in 1 quarter.
Capital Performance Advisors's Novavax position peaked at $518 in Q3 2024.
234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.